Synthesis, Molecular Modeling, and Biological Evaluation of Novel RAD51 Inhibitors

Overview

Journal Eur J Med Chem

Specialty Chemistry

Date 2015 Apr 16

PMID 25874343

Citations 22

Authors

Jiewen Zhu

Hongyuan Chen

Xuning Emily Guo

Xiao-Long Qiu

Chun-Mei Hu

A Richard Chamberlin

Wen-Hwa Lee

Affiliations

Soon will be listed here.

Abstract

RAD51 recombinase plays a critical role for cancer cell proliferation and survival. Targeting RAD51 is therefore an attractive strategy for treating difficult-to-treat cancers, e.g. triple negative breast cancers which are often resistant to existing therapeutics. To this end, we have designed, synthesized and evaluated a panel of new RAD51 inhibitors, denoted IBR compounds. Among these compounds, we have identified a novel small molecule RAD51 inhibitor, IBR120, which exhibited a 4.8-fold improved growth inhibition activity in triple negative human breast cancer cell line MBA-MD-468. IBR120 also inhibited the proliferation of a broad spectrum of other cancer cell types. Approximately 10-fold difference between the IC50 values in normal and cancer cells were observed. Moreover, IBR120 was capable of disrupting RAD51 multimerization, impairing homologous recombination repair, and inducing apoptotic cell death. Therefore, these novel RAD51 inhibitors may serve as potential candidates for the development of pharmaceutical strategies against difficult-to-treat cancers.

Citing Articles

Enantioselective synthesis of α-tetrasubstituted (1-indolizinyl) (diaryl)-methanamines chiral phosphoric acid catalysis.

Zhong J, Pan R, Lin X RSC Adv. 2024; 14(2):1106-1113.

PMID: 38174273 PMC: 10759308. DOI: 10.1039/d3ra07636a.

Let's not take DNA breaks for granted. The importance of direct detection of DNA breaks for the successful development of DDR inhibitors.

Solarczyk K, Kordon-Kiszala M Front Cell Dev Biol. 2023; 11:1118716.

PMID: 36968210 PMC: 10034645. DOI: 10.3389/fcell.2023.1118716.

Sulfur-Phenolate Exchange as a Mild, Fast, and High-Yielding Method toward the Synthesis of Sulfonamides.

van den Boom A, Zuilhof H Org Lett. 2023; 25(5):788-793.

PMID: 36720015 PMC: 9926510. DOI: 10.1021/acs.orglett.2c04292.

Targeting RAD51-Mediated Homologous Recombination as a Treatment for Advanced Solid and Hematologic Malignancies: Opportunities and Challenges Ahead.

Tsang E, Munster P Onco Targets Ther. 2022; 15:1509-1518.

PMID: 36536949 PMC: 9758980. DOI: 10.2147/OTT.S322297.

Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer.

Taylor S, Arends M, Langdon S Explor Target Antitumor Ther. 2022; 1(1):26-52.

PMID: 36046263 PMC: 9400734. DOI: 10.37349/etat.2020.00003.

References

Qiu X, Zhu J, Wu G, Lee W, Chamberlin A . Stereoselective synthesis of chiral IBR2 analogues. J Org Chem. 2009; 74(5):2018-27. DOI: 10.1021/jo802607f. View

Chen P, Chen C, Chen Y, Xiao J, Sharp Z, Lee W . The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc Natl Acad Sci U S A. 1998; 95(9):5287-92. PMC: 20253. DOI: 10.1073/pnas.95.9.5287. View

Ward A, Khanna K, Wiegmans A . Targeting homologous recombination, new pre-clinical and clinical therapeutic combinations inhibiting RAD51. Cancer Treat Rev. 2014; 41(1):35-45. DOI: 10.1016/j.ctrv.2014.10.006. View

Robu M, Inman R, Cox M . RecA protein promotes the regression of stalled replication forks in vitro. Proc Natl Acad Sci U S A. 2001; 98(15):8211-8. PMC: 37423. DOI: 10.1073/pnas.131022698. View

Chen C, Chen P, Zhong Q, Sharp Z, Lee W . Expression of BRC repeats in breast cancer cells disrupts the BRCA2-Rad51 complex and leads to radiation hypersensitivity and loss of G(2)/M checkpoint control. J Biol Chem. 1999; 274(46):32931-5. DOI: 10.1074/jbc.274.46.32931. View

Yu W, Mei Y, Kang Y, Hua Z, Jin Z . Improved procedure for the oxidative cleavage of olefins by OsO4-NaIO4. Org Lett. 2004; 6(19):3217-9. DOI: 10.1021/ol0400342. View

Maacke H, Jost K, Opitz S, Miska S, Yuan Y, Hasselbach L . DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene. 2000; 19(23):2791-5. DOI: 10.1038/sj.onc.1203578. View

Qiao G, Wu Y, Yang X, Zhong W, Xie D, Guan X . High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br J Cancer. 2005; 93(1):137-43. PMC: 2361489. DOI: 10.1038/sj.bjc.6602665. View

Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, Nowicki M . BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell. 2001; 8(4):795-806. DOI: 10.1016/s1097-2765(01)00357-4. View

10.

Pierce A, Johnson R, Thompson L, Jasin M . XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev. 1999; 13(20):2633-8. PMC: 317094. DOI: 10.1101/gad.13.20.2633. View

11.

Raderschall E, Stout K, Freier S, Suckow V, Schweiger S, Haaf T . Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res. 2002; 62(1):219-25. View

12.

Klein H . The consequences of Rad51 overexpression for normal and tumor cells. DNA Repair (Amst). 2008; 7(5):686-93. PMC: 2430071. DOI: 10.1016/j.dnarep.2007.12.008. View

13.

Zhu J, Zhou L, Wu G, Konig H, Lin X, Li G . A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia. EMBO Mol Med. 2013; 5(3):353-65. PMC: 3598077. DOI: 10.1002/emmm.201201760. View

14.

Richardson C, Stark J, Ommundsen M, Jasin M . Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability. Oncogene. 2004; 23(2):546-53. DOI: 10.1038/sj.onc.1207098. View

15.

Hudis C, Gianni L . Triple-negative breast cancer: an unmet medical need. Oncologist. 2011; 16 Suppl 1:1-11. DOI: 10.1634/theoncologist.2011-S1-01. View

16.

Pellegrini L, Yu D, Lo T, Anand S, Lee M, Blundell T . Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature. 2002; 420(6913):287-93. DOI: 10.1038/nature01230. View

17.

Wang Y, Song J, Hong R, Li H, Deng L . Asymmetric Friedel-crafts reaction of indoles with imines by an organic catalyst. J Am Chem Soc. 2006; 128(25):8156-7. PMC: 3161403. DOI: 10.1021/ja062700v. View

18.

Curtin N . DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer. 2012; 12(12):801-17. DOI: 10.1038/nrc3399. View

19.

Flygare J, Falt S, Ottervald J, Castro J, Dackland AL , Hellgren D . Effects of HsRad51 overexpression on cell proliferation, cell cycle progression, and apoptosis. Exp Cell Res. 2001; 268(1):61-9. DOI: 10.1006/excr.2001.5265. View

20.

Peddi P, Ellis M, Ma C . Molecular basis of triple negative breast cancer and implications for therapy. Int J Breast Cancer. 2012; 2012:217185. PMC: 3262606. DOI: 10.1155/2012/217185. View